Table 6.
Ongoing lenalidomide-based regime trials.
| Name | Phase | Age | Histology | Drugs | Status |
|---|---|---|---|---|---|
| NCT01415752 | II | >60 ys | Untreated MCL | RBV + RL | Ongoing and recruiting |
| NCT01316523 | II | >18 ys | Untreated indolent NHL | RL | Ongoing and recruiting |
| NCT00695786 | II | >18 ys | Untreated indolent NHL | RL | Ongoing and recruiting |
| FIL R2-B | II | >18 ys | Untreated indolent NHL | RBL | Ongoing and recruiting |
RBV: rituximab, bendamustine, bortezomib; RL: rituximab, lenalidomide; RBL: rituximab, bendamustine, lenalidomide.